Browsing Tag
AstraZeneca
161 posts
Avacta’s (AIM: AVCT) AVA6103 human data: What is proven before the 2027 efficacy test?
Avacta has reported preliminary controlled-release evidence from 19 patients treated with AVA6103, but tumour-selective delivery and clinical efficacy remain unconfirmed. Its latest ÂŁ12.5 million financing places additional attention on the anticipated 2027 results.
Summit Therapeutics (NASDAQ: SMMT) gives back most of 23% spike after AstraZeneca’s $2bn investment
AstraZeneca is investing $2 billion in Summit Therapeutics at an $18.36 common-equivalent price, yet Summit closed at only $16.39 after touching $19.01, showing that strategic validation has not erased the clinical and regulatory risk around ivonescimab.
Avacta AVA6103 clears clinical mechanism hurdle as 2027 efficacy test moves into focus
Avacta Group’s first human AVA6103 data show controlled exatecan release and encouraging tolerability at doses above conventional exatecan’s published maximum tolerated level, strengthening the preCISION platform thesis while leaving clinical efficacy as the next decisive test.
Clever Culture Systems (ASX: CC5) wins two more Novo Nordisk APAS orders
Clever Culture Systems Limited has received a purchase order from Novo Nordisk for two additional APAS Independence instruments and a custom laboratory-system integration, moving the pharmaceutical group from evaluation into formal global validation ahead of possible wider deployment.
Upstream Bio gains FDA alignment for pivotal verekitug trials across asthma and nasal polyps
Upstream Bio sets Phase 3 plans for quarterly verekitug in severe asthma and CRSwNP. See what FDA alignment means for the biotech’s growth strategy.
Tempus AI company profile: How diagnostics, health data and AI are building a precision medicine platform
Tempus AI, Inc. has built a precision medicine business around genomic diagnostics, multimodal health data, artificial intelligence and pharmaceutical research services. Ambry Genetics, Deep 6 AI, Paige and OneOme have widened that platform, while the proposed Personalis acquisition could bring molecular residual disease technology, laboratory economics and longitudinal cancer monitoring more tightly inside the company.
Nuvectis Pharma’s ciprocopan approval validates its Haisco deal but raises the execution stakes
Nuvectis Pharma gains ciprocopan validation in China, but licensing costs, dilution and ex-China execution will determine its real value.
Avacta (AIM: AVCT) just paid down ÂŁ3.67m of bond debt in cash. The real question is what AVA6103 does next.
Avacta cleared bond debt in cash and reaches its AVA6103 readout on funded runway. The next six months decide whether pre|CISION reads as one drug or a platform.
Ionis Pharmaceuticals (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails, Alnylam Amvuttra and BridgeBio Attruby emerge as clear beneficiaries
Ionis (IONS) drops 21% as Wainua Phase 3 ATTR-CM trial fails primary endpoint. Peak sales cut to $4B. Alnylam and BridgeBio benefit from the reset.
Racura Oncology (ASX:RAC): Will HARNESS-1 reset its valuation?
Racura Oncology has funded three cancer trials, but RAC shares remain far below their high. HARNESS-1 must now turn clinical progress into evidence.